Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Nichi-Iko Pharmaceutical Co Ltd (4541)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Nichi Iko Pharmaceutical historical data, for real-time data please try another search
35.0 0.0    0.00%
28/03 - Delayed Data. Currency in JPY ( Disclaimer )
Type:  Equity
Market:  Japan
ISIN:  JP3687200000 
  • Volume: 0
  • Bid/Ask: 35.0 / 36.0
  • Day's Range: 35.0 - 36.0
Nichi Iko Pharmaceutical 35.0 0.0 0.00%

4541 Income Statement

 
Featured here, the Income Statement (earnings report) for Nichi-Iko Pharmaceutical Co Ltd, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Income Statement
Period Ending: 2022
31/12
2022
30/09
2022
30/06
2022
31/03
Total Revenue 47462 44188 47062 44168
Revenue 47462 44188 47062 44168
Other Revenue, Total - - - -
Cost of Revenue, Total 49419 55017 44061 47196
Gross Profit -1957 -10829 3001 -3028
Total Operating Expenses 60859 95482 53611 56940
Selling/General/Admin. Expenses, Total 7300 6861 6867 8044
Research & Development 931 511 1715 1615
Depreciation / Amortization 1800 2679 2459 3397
Interest Expense (Income) - Net Operating -448 -917 -492 -1339
Unusual Expense (Income) - - - -
Other Operating Expenses, Total 1857 31331 -999 -1973
Operating Income -13397 -51294 -6549 -12772
Interest Income (Expense), Net Non-Operating - - - 1140
Gain (Loss) on Sale of Assets - - - 201
Other, Net 3141 -611 -2349 80600
Net Income Before Taxes -16538 -50683 -4200 -93573
Provision for Income Taxes 14 111 185 -4060
Net Income After Taxes -16552 -50794 -4385 -89513
Minority Interest -147 56 227 379
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items -16341 -50617 -4200 -89280
Total Extraordinary Items - - - -
Net Income -16341 -50617 -4200 -89280
Total Adjustments to Net Income - - - -
Income Available to Common Excluding Extraordinary Items -16341 -50617 -4200 -89280
Dilution Adjustment 0.411 0.735 0.113 -0.23
Diluted Net Income -16341.41 -50617.73 -4200.11 -89279.77
Diluted Weighted Average Shares 70.47 70.46 70.44 70.15
Diluted EPS Excluding Extraordinary Items -231.9 -718.4 -59.63 -1272.79
DPS - Common Stock Primary Issue - - - -
Diluted Normalized EPS -143.69 -447.07 -34.64 -103.55
* In Millions of JPY (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

4541 Comments

Write your thoughts about Nichi-Iko Pharmaceutical Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email